Home › Research › Mild cognitive impairment
Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity
Bjørn‐Eivind Kirsebom, Fernando González‐Ortiz, Sinthujah Vigneswaran, Geir Bråthen, Ragnhild Eide Skogseth, Berglind Gísladóttir, Peter Harrison, Jonas Alexander Jarholm et al.. Alzheimer s & Dementia, 2025-05-01
Topic: Brain proteins, microglia and lab models
Plain-language summary
Three progression clusters emerged in both cohorts: stable cognition, slow decline, and rapid decline-each including cases initially classified as CN or MCI. Baseline plasma p-tau217 was linked to progression risk in both cohorts, whereas longitudinal increases in Cohort 1 were steepest in rapid decliners. Plasma p-tau217 may aid in capturing clinical heterogeneity and support stratification and monitoring of disease progression in clinical trials. HIGHLIGHTS: k-Means found stable, slow, and rapid cognitive decline clusters in amyloid beta-positive (Aβ+) cases. Higher baseline plasma phosphorylated tau-217 (p-tau217) levels predicted faster cognitive decline. Longitudinal increases in plasma p-tau217 were steepest in rapid decliners. Plasma p-tau217 tracks clinical progression heterogeneity in Aβ+ cases. Cognitive stage and amyloid alone may miss severity and risk in early-stage Alzheimer's disease.
What this study adds
Evidence grade: Moderate
This is a follow-up (cohort) study of 186 participants. Repeated plasma p-tau217 measurements identified stable, slow and rapid cognitive decline clusters, and higher baseline levels predicted faster decline in amyloid-beta-positive cases. The authors say plasma p-tau217 may help capture clinical heterogeneity and support stratification and monitoring in clinical trials, which is about tracking disease rather than treating it.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Kirsebom, B., González‐Ortiz, F., Vigneswaran, S., Bråthen, G., Skogseth, R. E., Gísladóttir, B., et al. (2025). Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity. Alzheimer s & Dementia. https://doi.org/10.1002/alz.70319
Vancouver
Kirsebom B, González‐Ortiz F, Vigneswaran S, Bråthen G, Skogseth RE, Gísladóttir B, et al. Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity. Alzheimer s & Dementia. 2025. doi:10.1002/alz.70319. PMID: 40442871.
BibTeX
@article{kirsebom2025-40442871,
author = {Kirsebom, Bjørn‐Eivind and González‐Ortiz, Fernando and Vigneswaran, Sinthujah and Bråthen, Geir and Skogseth, Ragnhild Eide and Gísladóttir, Berglind and Harrison, Peter and Jarholm, Jonas Alexander and others},
title = {{Repeated plasma p‐tau217 measurements to monitor clinical progression heterogeneity}},
journal = {Alzheimer s \& Dementia},
year = {2025},
doi = {10.1002/alz.70319},
pmid = {40442871},
url = {https://doi.org/10.1002/alz.70319}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Three progression clusters emerged in both cohorts: stable cognition, slow decline, and rapid decline-each including cases initially classified as CN or MCI.
- Baseline plasma p-tau217 was linked to progression risk in both cohorts, whereas longitudinal increases in Cohort 1 were steepest in rapid decliners.
- Plasma p-tau217 may aid in capturing clinical heterogeneity and support stratification and monitoring of disease progression in clinical trials.
- HIGHLIGHTS: k-Means found stable, slow, and rapid cognitive decline clusters in amyloid beta-positive (Aβ+) cases.
- Higher baseline plasma phosphorylated tau-217 (p-tau217) levels predicted faster cognitive decline.
Why it matters
Repeated plasma p-tau217 measurements identified stable, slow and rapid cognitive decline clusters, and higher baseline levels predicted faster decline in amyloid-beta-positive cases. The authors say plasma p-tau217 may help capture clinical heterogeneity and support stratification and monitoring in clinical trials, which is about tracking disease rather than treating it.
Study details
- Study designlongitudinal study
- Participants186
- Evidence strengthModerate
How this study scored 63/100
Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for effect reported and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s & Dementia) |
| Journal's citation record | 2 / 4 | Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29) |
| Study design | 7 / 12 | A longitudinal study following the same people over time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 2 / 4 | 186 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 16 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 5.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 10.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 2 other studies in this library |
| Still being cited | 2 / 4 | Cited 16 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Kaj Blennow: h-index 220 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 23 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40442871) |
| Free to read | 2 / 2 | Free to read |
| Total | 63 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Mild cognitive impairment from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.